A synergistic interaction between HDAC- and PARP inhibitors in childhood tumors with chromothripsis

Umar Khalid, Milena Simovic, Linda A. Hammann, Murat Iskar, John K.L. Wong, Rithu Kumar, Manfred Jugold, Martin Sill, Michiel Bolkestein, Thorsten Kolb, Michaela Hergt, Frauke Devens, Jonas Ecker, Marcel Kool, Till Milde, Frank Westermann, Axel Benner, Joe Lewis, Sascha Dietrich, Stefan M. PfisterPeter Lichter, Marc Zapatka, Aurélie Ernst

Onderzoeksoutput: Bijdrage aan tijdschriftArtikelpeer review

5 Citaten (Scopus)


Chromothripsis is a form of genomic instability characterized by the occurrence of tens to hundreds of clustered DNA double-strand breaks in a one-off catastrophic event. Rearrangements associated with chromothripsis are detectable in numerous tumor entities and linked with poor prognosis in some of these, such as Sonic Hedgehog medulloblastoma, neuroblastoma and osteosarcoma. Hence, there is a need for therapeutic strategies eliminating tumor cells with chromothripsis. Defects in DNA double-strand break repair, and in particular homologous recombination repair, have been linked with chromothripsis. Targeting DNA repair deficiencies by synthetic lethality approaches, we performed a synergy screen using drug libraries (n = 375 compounds, 15 models) combined with either a PARP inhibitor or cisplatin. This revealed a synergistic interaction between the HDAC inhibitor romidepsin and PARP inhibition. Functional assays, transcriptome analyses and in vivo validation in patient-derived xenograft mouse models confirmed the efficacy of the combinatorial treatment.

Originele taal-2Engels
Pagina's (van-tot)590-606
Aantal pagina's17
TijdschriftInternational Journal of Cancer
Nummer van het tijdschrift4
StatusGepubliceerd - 15 aug. 2022


Duik in de onderzoeksthema's van 'A synergistic interaction between HDAC- and PARP inhibitors in childhood tumors with chromothripsis'. Samen vormen ze een unieke vingerafdruk.

Citeer dit